SlideShare uma empresa Scribd logo
1 de 21
STANISLAV ALVARO CARDONA MEDICINE STUDENT INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME   CDK1 INHIBITION SENSITISES AND TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   
FOLDING
FOLDING
The ovarian cancer is one of the most common in women. Some molecular particles are important to stop it. Inhibitors of the enzyme poly (ADP-ribose polymerase), or PARP, in a study to stop the development of some tumours
INTEGRATED ANALYSES OF THE  OVARIAN CANCER GENOME     July 4th 2011
INTEGRATED ANALYSES OF THE  OVARIAN CANCER GENOME     Ovarian cancer is a malignant tumor that arises in any part of the ovary due to mutation and cell proliferation influenced by genetic, environmental or hereditary factors.
Its prognosis is good, on the rare occasions when diagnosed early Ovarian cancer is the fifth most common cancer in women in the UK, all over the world, representing approximately 4% of all cancers diagnosed in women INTEGRATED ANALYSES OF THE  OVARIAN CANCER GENOME    
INTEGRATED ANALYSES OF THE  OVARIAN CANCER GENOME     There are several genes involved in the development of this pathology as BRCA1  BRCA2  RB1 NF1 FAT3 CSMD3 GABRA6 CDK12
INTEGRATED ANALYSES OF THE  OVARIAN CANCER GENOME     This was determined by a genome study of women with ovarian cancer which showed mutations in the mRNA during protein synthesis
OBSERVATION I think that this is an important step in the science, because this would be the beginning of the treatment of many pathologies Understanding the genetic material allows find the answers for many medical riddles
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION    July 4th 2011
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION    Inhibitors of the enzyme poly (ADP-ribose) polymerase, or PARP, are among the most promising drugs currently in development as anti-tumour agents.
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION    BRCA1 "breast cancer 1"   is a tumor suppressor gene, which regulate the cell cycle and prevent uncontrolled proliferation.   CDK1 is a highly conserved protein that functions as a serine / threonine kinase, is encoded by the gene cdc2. Phosphorylation of these proteins control cell cycle progression
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION    A combination of a PARP inhibitor with a Cdk1 inhibitor also showed reduced tumour growth and prolonged survival compared to treatment with one or no inhibitors in a mouse model of lung adenocarcinoma.
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION    Inhibition of Cdk1 is likely to sensitise tumours with wild type BRCA1 to PARP inhibition, and that a combination of inhibitors of these two enzymes may be a useful treatment for these tumours
OBSERVATION That experiments are fundamental to know how the human life is affected begging in the littlest process that define the whole life
MEDICAL UTILITY
MEDICAL UTILITY The study of the human genome could shed any information about each individual and that is where the solution begins each pathology to develop it.
MEDICAL UTILITY New experiments with enzymes have led to cures for various types of cancer, starting with the molecular basis of such tumors which involve cell division and proper transfer of genetic information. Molecular biology is the basis for understanding the processes that lead to cause such conditions, so find a solutions or improvements to the health of people
BIBLIOGRAPHY ,[object Object],[object Object],[object Object]
THANK YOU…

Mais conteúdo relacionado

Mais procurados

Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
espontanea
 
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
European School of Oncology
 
SURE Conference Abstract
SURE Conference Abstract SURE Conference Abstract
SURE Conference Abstract
Eric Hillpot
 
Plegable pp1
Plegable pp1Plegable pp1
Plegable pp1
MafeU
 
Plegable pp1
Plegable pp1Plegable pp1
Plegable pp1
MafeU
 

Mais procurados (19)

Molecular Biology Seminary by Nicolas calle
Molecular Biology Seminary by Nicolas calleMolecular Biology Seminary by Nicolas calle
Molecular Biology Seminary by Nicolas calle
 
Protocol for the Treatment Prostate Cancer - Dr Serge Jurasunas
Protocol for the Treatment Prostate Cancer - Dr Serge JurasunasProtocol for the Treatment Prostate Cancer - Dr Serge Jurasunas
Protocol for the Treatment Prostate Cancer - Dr Serge Jurasunas
 
Seminario Biologia molecular pdf
Seminario Biologia molecular pdfSeminario Biologia molecular pdf
Seminario Biologia molecular pdf
 
Dna-Repair
Dna-RepairDna-Repair
Dna-Repair
 
Breast Cancer Facts, brought to you by Spencer Trask & Co.
Breast Cancer Facts, brought to you by Spencer Trask & Co.Breast Cancer Facts, brought to you by Spencer Trask & Co.
Breast Cancer Facts, brought to you by Spencer Trask & Co.
 
Role of tumour markers in clinical practice
Role of tumour markers in clinical practiceRole of tumour markers in clinical practice
Role of tumour markers in clinical practice
 
Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
Level of Tumor Protein Indicates Chances Cancer Will Spread AND Malfunctionin...
 
Alfred knudson and the two hit hypothesis
Alfred knudson and the two hit hypothesisAlfred knudson and the two hit hypothesis
Alfred knudson and the two hit hypothesis
 
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Cerv...
 
Tumour Markers
Tumour Markers Tumour Markers
Tumour Markers
 
SURE Conference Abstract
SURE Conference Abstract SURE Conference Abstract
SURE Conference Abstract
 
tumor markers
tumor markerstumor markers
tumor markers
 
Tumour marker
Tumour markerTumour marker
Tumour marker
 
SERUM TUMOR MARKERS
SERUM TUMOR MARKERSSERUM TUMOR MARKERS
SERUM TUMOR MARKERS
 
Epithelial tumor markers
Epithelial tumor markersEpithelial tumor markers
Epithelial tumor markers
 
Prophylaxis and early diagnosis of breast cancer
Prophylaxis and early diagnosis of breast cancerProphylaxis and early diagnosis of breast cancer
Prophylaxis and early diagnosis of breast cancer
 
Papillary thyroid carcinoma
Papillary thyroid carcinomaPapillary thyroid carcinoma
Papillary thyroid carcinoma
 
Plegable pp1
Plegable pp1Plegable pp1
Plegable pp1
 
Plegable pp1
Plegable pp1Plegable pp1
Plegable pp1
 

Destaque

Ici 3 company profile
Ici 3 company profileIci 3 company profile
Ici 3 company profile
Kevin Lee
 
Virtual presentation assignment 1
Virtual presentation assignment 1Virtual presentation assignment 1
Virtual presentation assignment 1
Stalgis
 
Journal 4 to 5
Journal 4  to 5Journal 4  to 5
Journal 4 to 5
Kevin Lee
 
Journal 1 to 3
Journal 1 to 3Journal 1 to 3
Journal 1 to 3
Kevin Lee
 
ICI project 1
ICI project 1ICI project 1
ICI project 1
Kevin Lee
 
Arvoredeamigos
ArvoredeamigosArvoredeamigos
Arvoredeamigos
Claudia FN
 

Destaque (8)

Ici 3 company profile
Ici 3 company profileIci 3 company profile
Ici 3 company profile
 
Virtual presentation assignment 1
Virtual presentation assignment 1Virtual presentation assignment 1
Virtual presentation assignment 1
 
Journal 4 to 5
Journal 4  to 5Journal 4  to 5
Journal 4 to 5
 
Site report
Site reportSite report
Site report
 
Journal 1 to 3
Journal 1 to 3Journal 1 to 3
Journal 1 to 3
 
ICI project 1
ICI project 1ICI project 1
ICI project 1
 
Arvoredeamigos
ArvoredeamigosArvoredeamigos
Arvoredeamigos
 
Powerpoint
PowerpointPowerpoint
Powerpoint
 

Semelhante a Ovarian Cancer

Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HRAlexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre Arcaro
 
An introduction to cancer
An introduction to cancerAn introduction to cancer
An introduction to cancer
Salman Ul Islam
 
Personalized Medicine
Personalized MedicinePersonalized Medicine
Personalized Medicine
noelle cloven
 
Use of Autoantibodies to detect the onset of breast cancer
Use of Autoantibodies to detect the onset of breast cancerUse of Autoantibodies to detect the onset of breast cancer
Use of Autoantibodies to detect the onset of breast cancer
Isabelle Chiu
 

Semelhante a Ovarian Cancer (20)

Gene therapy
Gene therapyGene therapy
Gene therapy
 
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HRAlexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
 
Naturopathic Oncology Slideshare316
Naturopathic Oncology Slideshare316Naturopathic Oncology Slideshare316
Naturopathic Oncology Slideshare316
 
Russell
RussellRussell
Russell
 
Seminario biologia molecular
Seminario biologia molecular Seminario biologia molecular
Seminario biologia molecular
 
TRIM 47 accelerates aerobic glycolysis and tumor progression through regulati...
TRIM 47 accelerates aerobic glycolysis and tumor progression through regulati...TRIM 47 accelerates aerobic glycolysis and tumor progression through regulati...
TRIM 47 accelerates aerobic glycolysis and tumor progression through regulati...
 
Anticancer
AnticancerAnticancer
Anticancer
 
An introduction to cancer
An introduction to cancerAn introduction to cancer
An introduction to cancer
 
Personalized medicine
Personalized medicinePersonalized medicine
Personalized medicine
 
Personalized Medicine
Personalized MedicinePersonalized Medicine
Personalized Medicine
 
August 2018 Dil Se Dil Tak Newsletter (FOGSI)
August 2018   Dil Se Dil Tak Newsletter (FOGSI)August 2018   Dil Se Dil Tak Newsletter (FOGSI)
August 2018 Dil Se Dil Tak Newsletter (FOGSI)
 
ajit tumor marker.pptx
ajit tumor marker.pptxajit tumor marker.pptx
ajit tumor marker.pptx
 
CERVICAL CANCER
CERVICAL CANCERCERVICAL CANCER
CERVICAL CANCER
 
Tumour marker
Tumour marker Tumour marker
Tumour marker
 
How to Understand and Treat Cancer with Molecular Markers
How to Understand and Treat Cancer with Molecular MarkersHow to Understand and Treat Cancer with Molecular Markers
How to Understand and Treat Cancer with Molecular Markers
 
Advances in the management of breast cancer
Advances in the management of breast cancerAdvances in the management of breast cancer
Advances in the management of breast cancer
 
Cancer and tumor markers
Cancer and tumor markersCancer and tumor markers
Cancer and tumor markers
 
Use of Autoantibodies to detect the onset of breast cancer
Use of Autoantibodies to detect the onset of breast cancerUse of Autoantibodies to detect the onset of breast cancer
Use of Autoantibodies to detect the onset of breast cancer
 
Breast carcinoma overview and recent advances in management
Breast carcinoma overview and recent advances in managementBreast carcinoma overview and recent advances in management
Breast carcinoma overview and recent advances in management
 
Current pancreatic cancer research 10 May 16
Current pancreatic cancer research 10 May 16Current pancreatic cancer research 10 May 16
Current pancreatic cancer research 10 May 16
 

Último

Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
panagenda
 
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
TrustArc
 
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
Muhammad Subhan
 

Último (20)

Google I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGoogle I/O Extended 2024 Warsaw
Google I/O Extended 2024 Warsaw
 
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
 
WebRTC and SIP not just audio and video @ OpenSIPS 2024
WebRTC and SIP not just audio and video @ OpenSIPS 2024WebRTC and SIP not just audio and video @ OpenSIPS 2024
WebRTC and SIP not just audio and video @ OpenSIPS 2024
 
WebAssembly is Key to Better LLM Performance
WebAssembly is Key to Better LLM PerformanceWebAssembly is Key to Better LLM Performance
WebAssembly is Key to Better LLM Performance
 
Intro to Passkeys and the State of Passwordless.pptx
Intro to Passkeys and the State of Passwordless.pptxIntro to Passkeys and the State of Passwordless.pptx
Intro to Passkeys and the State of Passwordless.pptx
 
Introduction to FIDO Authentication and Passkeys.pptx
Introduction to FIDO Authentication and Passkeys.pptxIntroduction to FIDO Authentication and Passkeys.pptx
Introduction to FIDO Authentication and Passkeys.pptx
 
2024 May Patch Tuesday
2024 May Patch Tuesday2024 May Patch Tuesday
2024 May Patch Tuesday
 
Intro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджераIntro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджера
 
Human Expert Website Manual WCAG 2.0 2.1 2.2 Audit - Digital Accessibility Au...
Human Expert Website Manual WCAG 2.0 2.1 2.2 Audit - Digital Accessibility Au...Human Expert Website Manual WCAG 2.0 2.1 2.2 Audit - Digital Accessibility Au...
Human Expert Website Manual WCAG 2.0 2.1 2.2 Audit - Digital Accessibility Au...
 
Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024
 
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
Easier, Faster, and More Powerful – Alles Neu macht der Mai -Wir durchleuchte...
 
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
TrustArc Webinar - Unified Trust Center for Privacy, Security, Compliance, an...
 
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
“Iamnobody89757” Understanding the Mysterious of Digital Identity.pdf
 
Long journey of Ruby Standard library at RubyKaigi 2024
Long journey of Ruby Standard library at RubyKaigi 2024Long journey of Ruby Standard library at RubyKaigi 2024
Long journey of Ruby Standard library at RubyKaigi 2024
 
Overview of Hyperledger Foundation
Overview of Hyperledger FoundationOverview of Hyperledger Foundation
Overview of Hyperledger Foundation
 
State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!
 
AI mind or machine power point presentation
AI mind or machine power point presentationAI mind or machine power point presentation
AI mind or machine power point presentation
 
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdfIntroduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
 
The Metaverse: Are We There Yet?
The  Metaverse:    Are   We  There  Yet?The  Metaverse:    Are   We  There  Yet?
The Metaverse: Are We There Yet?
 
Continuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
Continuing Bonds Through AI: A Hermeneutic Reflection on ThanabotsContinuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
Continuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
 

Ovarian Cancer

  • 1. STANISLAV ALVARO CARDONA MEDICINE STUDENT INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME CDK1 INHIBITION SENSITISES AND TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION  
  • 4. The ovarian cancer is one of the most common in women. Some molecular particles are important to stop it. Inhibitors of the enzyme poly (ADP-ribose polymerase), or PARP, in a study to stop the development of some tumours
  • 5. INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME   July 4th 2011
  • 6. INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME   Ovarian cancer is a malignant tumor that arises in any part of the ovary due to mutation and cell proliferation influenced by genetic, environmental or hereditary factors.
  • 7. Its prognosis is good, on the rare occasions when diagnosed early Ovarian cancer is the fifth most common cancer in women in the UK, all over the world, representing approximately 4% of all cancers diagnosed in women INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME  
  • 8. INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME   There are several genes involved in the development of this pathology as BRCA1 BRCA2 RB1 NF1 FAT3 CSMD3 GABRA6 CDK12
  • 9. INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME   This was determined by a genome study of women with ovarian cancer which showed mutations in the mRNA during protein synthesis
  • 10. OBSERVATION I think that this is an important step in the science, because this would be the beginning of the treatment of many pathologies Understanding the genetic material allows find the answers for many medical riddles
  • 11. CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   July 4th 2011
  • 12. CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   Inhibitors of the enzyme poly (ADP-ribose) polymerase, or PARP, are among the most promising drugs currently in development as anti-tumour agents.
  • 13. CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   BRCA1 "breast cancer 1" is a tumor suppressor gene, which regulate the cell cycle and prevent uncontrolled proliferation. CDK1 is a highly conserved protein that functions as a serine / threonine kinase, is encoded by the gene cdc2. Phosphorylation of these proteins control cell cycle progression
  • 14. CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   A combination of a PARP inhibitor with a Cdk1 inhibitor also showed reduced tumour growth and prolonged survival compared to treatment with one or no inhibitors in a mouse model of lung adenocarcinoma.
  • 15. CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION   Inhibition of Cdk1 is likely to sensitise tumours with wild type BRCA1 to PARP inhibition, and that a combination of inhibitors of these two enzymes may be a useful treatment for these tumours
  • 16. OBSERVATION That experiments are fundamental to know how the human life is affected begging in the littlest process that define the whole life
  • 18. MEDICAL UTILITY The study of the human genome could shed any information about each individual and that is where the solution begins each pathology to develop it.
  • 19. MEDICAL UTILITY New experiments with enzymes have led to cures for various types of cancer, starting with the molecular basis of such tumors which involve cell division and proper transfer of genetic information. Molecular biology is the basis for understanding the processes that lead to cause such conditions, so find a solutions or improvements to the health of people
  • 20.